Novartis off to strong start with Zolgensma

Oct. 22, 2019 8:43 AM ETNovartis AG (NVS)NVSBy: Douglas W. House, SA News Editor1 Comment
  • Novartis' (NYSE:NVS) gene therapy Zolgensma (anasemnogene abeparvovec-xioi) generated $160M in sales in Q3, well above analysts' projections of ~$98M, its first full quarter on the market.
  • The FDA approved Zolgensma, priced at a hefty $2.1M per patient, in May for children younger than two years old with spinal muscular atrophy.
  • On a call with reporters today, CEO Vas Narasimhan said that 99% of eligible patients were receiving the gene therapy, on average within 30 days of requesting it.
  • To address payer concerns over the price, the company is offering outcomes-based deals where a portion of the cost is refunded if Zolgensma proves ineffective in addition to an option to pay for the treatment in five equal installments over five years.
  • Shares are down 1% premarket after Q3 results were released earlier this morning.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.